TenSixteen Bio

TenSixteen Bio is a precision medicine company pioneering the study of Clonal Hematopoiesis of Indeterminate Potential (CHIP) to treat and prevent age-related diseases. By leveraging large-scale genomic and clinical datasets, the company identifies somatic mutations in blood cells that serve as early drivers of cardiovascular disease, cancer, and inflammation. TenSixteen Bio is developing a suite of diagnostic tools and therapeutic programs designed to intervene early in the disease trajectory. Their platform integrates human genetics with deep biological insights to transform how chronic diseases are managed. The company was launched with significant backing from leading life science investors to bridge the gap between genomics and clinical care.